Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 19/2004

01-10-2004 | Adis Drug Profile

Lumiracoxib

A Viewpoint by Hyman Tannenbaum

Author: Hyman Tannenbaum

Published in: Drugs | Issue 19/2004

Login to get access

Excerpt

In 1999, the WHO designated a new subclass of NSAIDs, which were termed coxibs. Coxibs distinguish themselves from the nonselective NSAIDs by selectively inhibiting the cyclo-oxygenase (COX)-2 enzyme. Celecoxib and rofecoxib, which have sulfonamide and methylsulfone side-chains, respectively, were among the first generation of coxibs. More recently, a second generation of coxibs (valdecoxib, etoricoxib and lumiracoxib), which have greater potency in inhibiting the COX-2 enzyme than their predecessors, have been developed. …
Literature
1.
Marshall PJ, Berry C, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2 [abstract no. SAT0013]. Ann Rheum Dis 2002; 61 Suppl. 1: 259
2.
Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis. Epub 2004 Feb 27
3.
Bitner M, Kattenhorn J, Hatfield C, et al. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract 2004 Apr; 58(4): 340–5PubMedCrossRef
4.
Pavelka K, Nayiager S, Kivitz A, et al. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: a 13-week, randomized, double-blind study [abstract no. FRI10107]. Ann Rheum Dis 2004 Jul; 63 Suppl. 1: 280
5.
Kivitz AJ, Nayiager S, Schimansky T, et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004 Jun 1; 19(11): 1189–98PubMedCrossRef
6.
Hawkey CJ, Karateev D, Codreanu C, et al. Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX189 compared with ibuprofen in osteoarthritis patients [abstract no. THU0226]. Ann Rheum Dis 2002; 61 Suppl. 1: 126
7.
Schnitzer TM, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 Aug 21; 364(9435): 665–74PubMedCrossRef
8.
Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 Aug 21; 364(9435): 675–84PubMedCrossRef
9.
Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2004; 51(4): 549–57CrossRef
10.
Geusens P, Alten R, Rovensky J, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: results of a randomized double-blind study [abstract no. 544]. Arthritis Rheum 2003; 48 (9 Suppl.): 242
11.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000 Nov 23; 343(21): 1520–8PubMedCrossRef
Metadata
Title
Lumiracoxib
A Viewpoint by Hyman Tannenbaum
Author
Hyman Tannenbaum
Publication date
01-10-2004
Publisher
Springer International Publishing
Published in
Drugs / Issue 19/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200464190-00010

Other articles of this Issue 19/2004

Drugs 19/2004 Go to the issue

Leading Article

Reactive Oxygen Species in the Cerebral Circulation

Adis Drug Profile

Anidulafungin

Review Article

Antiepileptic Drugs in the Treatment of Anxiety Disorders

Guest Commentary

Lumiracoxib

Therapy In Practice

Management of Invasive Candidiasis in Critically Ill Patients

Adis Drug Profile

Anidulafungin